Syzonc

SyzOnc is a Philadelphia-based biotechnology company founded in 2023 that develops innovative therapies for solid tumor cancers, including sarcoma, liver, and pancreatic cancer, particularly targeting patients with limited treatment options. The company leverages a systems-level, tech-enabled approach that incorporates AI tools and advanced assays such as Cell Painting to discover and develop tumor microenvironment modulators and immunotherapy solutions. SyzOnc operates out of B+labs in Philadelphia and is led by a founding team with expertise in 3D solid tumor biology and AI-driven drug discovery. With a small team of around five employees, SyzOnc is currently in the pre-seed stage and remains privately held. Their business model centers on the research and development of oncology therapeutics intended for commercialization or partnership with larger pharmaceutical entities.

Recent Posts by Syzonc

1-1 of 1